LL-37 is a naturally occurring human peptide with a real and well-studied role
in innate immunity — and a more complex, double-edged biology than most
marketing acknowledges.
Chemical identity & structure.
LL-37 is a 37-amino-acid peptide — the only human member of the cathelicidin
family of antimicrobial peptides. Its name comes from its first two residues
(two leucines) and its length. It is produced naturally by immune cells and
epithelial tissues as part of the body's first-line defense.
Mechanism of action.
LL-37 has several reported activities. As an antimicrobial peptide it can
directly disrupt the membranes of bacteria and other microbes. It also has
immunomodulatory roles — influencing immune-cell recruitment and inflammatory
signaling — and roles in wound healing and angiogenesis. Importantly, LL-37's
biology is context-dependent: it can be protective, but dysregulated LL-37
is also implicated in certain inflammatory and autoimmune conditions. It is not
a simple "good" molecule.
Key research findings.
LL-37 has a substantial research literature in immunology, microbiology,
dermatology, and wound healing. Research has examined both its protective
antimicrobial and wound-healing roles and its involvement in inflammatory skin
disease, where excess or dysregulated LL-37 appears to contribute to pathology.
The research / citation base.
LL-37 has a genuine, sizable peer-reviewed research literature as an endogenous
human peptide. It is not an approved drug as an administered therapeutic,
and the context-dependent nature of its biology is a real reason for caution
about administering it.
Human clinical trial data.
In the first-in-man randomized trial by Grönberg et al. (2014), 34 participants with hard-to-heal venous leg ulcers received twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo during a 4-week double-blind treatment phase (PubMed). In the phase IIb HEAL LL-37 trial by Mahlapuu et al. (2021), 148 patients received topical LL-37 at 0.5 or 1.6 mg/mL or placebo with compression therapy, and the trial found no significant improvement in healing in the full study population (PubMed).
Quality & sourcing notes.
As a 37-residue peptide, a credible COA should confirm the full sequence by mass
spectrometry and report HPLC purity. Synthesis of a peptide this length is more
demanding, so purity documentation matters.
*Research-use note: Educational summary of published research. LL-37 is not an
approved drug and has context-dependent (sometimes pro-inflammatory) biology;
this is research context only and not medical advice.*